Form 4: Medifast CEO Boosts Stake with Grants and Purchases

Medifast's Chairman and CEO, Daniel R. Chard, reported a net increase in his beneficial ownership through equity grants and open market purchases.

Summary

• Daniel R. Chard, Chairman & CEO of Medifast Inc. (MED), reported multiple transactions in the company's common stock.
• Acquired 17,678 shares indirectly through a joint account at a weighted average price of $10.11 per share on March 20, 2026.
• Received a grant of 36,968 restricted stock units (RSUs) at a $0 cost on March 25, 2026, which will vest in three equal annual installments.
• Received 4,827 shares from the vesting and settlement of previously granted performance stock units (PSUs) at a $0 cost on March 25, 2026, following certification of performance criteria.
• Disposed of a total of 29,808 shares across three separate transactions (7,075, 2,638, and 20,095 shares) between March 13 and March 25, 2026, to cover withholding taxes upon RSU vesting, at prices ranging from $9.59 to $10.05.
• His direct beneficial ownership after these transactions stands at 188,233 shares.
• Indirect beneficial ownership includes 17,678 shares held jointly with his spouse and 149,698.352 shares held by The Dan and Allyson Family Irrevocable Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting management's continued equity accumulation through grants and open market purchases, which typically indicates confidence in the company's prospects, despite routine tax-related dispositions.

Positives

• Acquisition of 17,678 shares through open market purchases by the CEO, signaling confidence in the company's valuation and future prospects.
• Grant of 36,968 restricted stock units (RSUs) at no cost, representing a significant future equity stake tied to continued service.
• Vesting of 4,827 performance stock units (PSUs) at no cost, indicating the achievement of previously set performance criteria by the company.

Negatives

• Disposition of 29,808 shares to cover tax obligations associated with the vesting of restricted stock units, which reduces the CEO's direct shareholdings.

Future Outlook

The 36,968 restricted stock units granted on March 25, 2026, are scheduled to vest in three equal annual installments, beginning on the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that insider transactions, particularly open market purchases and performance-based equity grants, can signal management's confidence in the company's future performance and strategic direction, aligning their interests with those of shareholders.

Related Party Transactions

• The reported transactions involve Daniel R. Chard, Chairman & CEO of Medifast Inc., and the issuer, which are inherently related party dealings.
• Indirect ownership through a joint account with his spouse and an irrevocable family trust also constitutes related party holdings.

Stakeholder Impact

• Shareholders: The net increase in insider ownership, particularly through open market purchases and performance-based grants, could be viewed positively as it aligns management's interests with shareholders. Routine tax-related dispositions are generally not a concern.
• Employees: The vesting of performance stock units indicates that company performance criteria were met, which could be a positive signal for employee morale and future incentive programs.

Next Steps

• The 36,968 restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date (March 25, 2027).

Key Dates

Recommendation

The filing indicates a net increase in beneficial ownership by the CEO, driven by equity grants and open market purchases, which is generally a positive sign of insider confidence. However, a significant portion of dispositions were for tax withholding, which is a routine event. The overall activity suggests a stable insider position rather than a strong signal for immediate buying or selling, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Medifast, MED, Daniel R. Chard, insider trading, Form 4, stock acquisition, restricted stock units, performance stock units, CEO, director, beneficial ownership, share grant, tax withholding